49 reports

  • REGION

SOUTH KOREA IS ONE OF THE FIRST MOVERS IN CELL AND GENE THERAPY.

  • Gene Therapy
  • Medical Biotechnology
  • Pathology
  • Therapy
  • Amgen Inc.

SUPPLIER POWER -High ##.

  • Biopharmaceutical
  • Medical Biotechnology
  • Pathology
  • Regenerative Medicine
  • Amgen Inc.

This collaboration focused on the development of BIIB##, an investigational AAV-based gene therapy for the treatment of XLRS, and BIIB##, an investigational AAV-based gene therapy for the treatment of XLRP.

  • Injectable Delivery
  • Pathology
  • Amgen Inc.
  • Antares Pharma, Inc.
  • Bayer AG
  • 8.1 References
  • Pipeline Landscape Assessment

In males (who have only one X chromosome), one altered copy of the gene is sufficient to cause the condition.

  • Clinical Trial
  • Genetic Disorder
  • Pathology
  • Therapy
  • Amgen Inc.
  • 7.2.4 DEALS BY MOLECULE TYPE, MOLECULAR TARGET AND VALUE
  • CARDIOVASCULAR DISEASE DRUGS MARKET, GLOBAL, CO-DEVELOPMENT DEALS WITH DISCLOSED DEAL VALUES, 2006-2017

Hypertension; ##(##): ## Johnston S, et al. (2016).

  • Cardiovascular Disease
  • Chronic Disease
  • Pathology
  • Amgen Inc.
  • Merck & Co., Inc.

Hoffmann-La Roche Sales by Region; 2018 ## ##.

  • Oncology
  • Pathology
  • World
  • Market Size
  • Amgen Inc.
  • 8.2 Abbreviations

Cell and gene therapies are slightly more common, accounting for ##. ##%.

  • Clinical Trial
  • Diabetes
  • Insulin
  • Pathology
  • Amgen Inc.

As shown in Figure ##C, the ' others' category is made up of antibodies (three products), fusion proteins (three products), conjugated mAbs (two products), proteins (two products), aptamers and gene therapies with one molecule each.

  • Musculoskeletal Disorder
  • Pathology
  • Therapy
  • Market Size
  • Amgen Inc.

The remaining ##% contains a range of less-common molecule types, including cell therapies, gene therapies, synthetic peptides and biologics.

  • Dermatological Condition
  • Dermatology
  • Pathology
  • Therapy
  • Amgen Inc.

ALTERNATE THERAPIES LOOM LARGE DEVELOPMENT OF GENE THERAPY-BASED PRODUCTS Gene therapy is one of the promising fields.

  • Medical Biotechnology
  • Pathology
  • Therapy
  • Market Size
  • Amgen Inc.

VBL Therapeutics' adenoviral gene therapy VB-## (ofranergene obadenovec) selectively induces TNFR## expression in tumor vasculature, resulting in tumor starvation.

  • Pathology
  • United States
  • Forecast
  • Product Initiative
  • Amgen Inc.

Arthritis Research Therapy; ##(##): ##-## Bridges D, et al. (2001).

  • Blood Disease
  • Cancer
  • Pathology
  • Therapy
  • Amgen Inc.

It is not limited to small molecules and contains a wide range of other molecule types such as mAbs, proteins, gene therapies, vaccines and cell therapies.

  • Autoimmune Disease
  • Immunology
  • Pathology
  • Therapy
  • Amgen Inc.

The remaining ##. ##% is made up of a range of less-common molecule types, including cell therapies, gene therapies and synthetic peptides.

  • Dermatology
  • Pathology
  • Pharmaceutical
  • Therapy
  • Amgen Inc.

The company' s drug platforms include biologics, small molecules, millamolecules, antibody-drug conjugates, gene therapy, RNA oligonucleotides and drug delivery technology.

  • Cancer
  • Pathology
  • Renal Cancer
  • Therapy
  • Amgen Inc.

You can easily book an appointment with one online.

  • Pathology
  • United States
  • World
  • Forecast
  • Amgen Inc.

She is a co-inventor on many issued US patents and applications related to projects on cell and gene therapies.

  • Clinical Trial
  • Pathology
  • United States
  • AbbVie Inc.
  • Amgen Inc.

Preface ##.

  • Pathology
  • Italy
  • United Kingdom
  • Market Size
  • Amgen Inc.
  • Cardiovascular Disease Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017
  • Cardiovascular Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017

Peptides, cell and gene therapies are all heavily represented in this pipeline, accounting for ##%, ##% and ##%, respectively.

  • Cardiovascular Disease
  • Chronic Disease
  • Pathology
  • Therapy
  • Amgen Inc.

Biologics include products such as enzymes, allergenics, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.

  • Cancer Immunotherapy
  • Pathology
  • Therapy
  • AbbVie Inc.
  • Amgen Inc.
  • NOVEL TREATMENT RESEARCH ACTIVITIES
  • NOVEL TREATMENT RESEARCH ACTIVITIES

MVX-ONCO-## consists of a device and gene therapy product.

  • Cancer
  • Pathology
  • Targeted Therapy
  • Therapy
  • Amgen Inc.

Low ## Low ## ## ## ## ## High ## ## ## ## High R& D High Low ## ## ## ## ## Upcoming mAbs STRATEGY STRENGTH MYLAN BUSINESS OVERVIEW Mylan was established in 1961 and is headquartered in Pennsylvania, US.

  • Breast Cancer
  • Pathology
  • Therapy
  • Amgen Inc.
  • Mylan Inc.

Low ## Low F.

  • Musculoskeletal Disorder
  • Pathology
  • World
  • Market Size
  • Amgen Inc.

(Inactive) EpiPharm AG DLX-## DLX-## DLX-## Preclinical mAb Tumor Necrosis Factor Alpha Toll-Like Receptor ##fMet-Leu-Phe Receptor, Toll-Like Receptor ## mAb Small molecule Adenosine Receptor A##a Undisclosed Neurotransmitter s and receptors Interleukin ## Beta GlaxoSmithKline Plc Canton

  • Dermatology
  • Pathology
  • Therapy
  • Market Size
  • Amgen Inc.

Urologia Internationalis; ##(##): ##-##.

  • Cancer Immunotherapy
  • Pathology
  • Therapy
  • Vaccine
  • Amgen Inc.

This includes cell therapies, gene therapies, antisense therapies, vaccines and peptides, with mean durations of ##. ##, ##. ##, ##. ##, ##. ## and ##. ##, respectively.

  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Pathology
  • Therapy
  • Amgen Inc.

Molecular Partners AG Phase I docetaxel Phase I KOS-## Ad/ PNP-F-araAMP VCN-## Vaccine for Small Cell Lung Cancer lifastuzumab vedotin trastuzumab biobetter Glycotope GmbH TVI-Breast-## TVI-Colon-## TVI-Lung-## TVI-Melanoma-## TVI-Ovary-## TVI-Prostate-

  • Cancer
  • Oncology
  • Pathology
  • Therapy
  • Amgen Inc.
  • Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 4, 2016
  • Hematological Cancers Therapeutics Market, Global, First-in-Class Products in Clinical Development, Part 2, 2016

Table ##: Hematological Cancers Therapeutics Market, Global, MALT## as a Therapeutic Target, 2016 + ##. ## Pipeline Programs that Target Interleukin-## Receptor Accessory Protein The interleukin-## receptor accessory protein (IL##RAP), also referred to as IL-## receptor ##, is a co-

  • Leukemia
  • Pathology
  • Therapy
  • Market Size
  • Amgen Inc.

One reason for noncompliance is safety issues.

  • Pathology
  • United States
  • World
  • Market Size
  • Amgen Inc.
  • Innovation

There are general biologics, mAbs, vaccines, proteins and peptides, and there are also products classed as cell therapies and gene therapies, as Figure ## shows.

  • Asthma
  • Pathology
  • Therapy
  • Amgen Inc.
  • Novartis AG